Overview:
Eosinophilic pneumonia is a pulmonary disease in which eosinophils accumulate in the lung and leads to disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere. Several different kinds of eosinophilic pneumonia exist and can occur in any age group. There are two types of eosinophilic pneumonia acute eosinophilic pneumonia (AEP) and chronic eosinophilic pneumonia (CEP). According to National Organization for Rare Disorders (NORD), individuals with AEP respond within days to high doses of corticosteroids, which usually are prescribed for two weeks. Corticosteroid therapy is initiated only after an infectious cause of pulmonary eosinophilia has been ruled out. Respiratory support can consist of either invasive or noninvasive mechanical ventilation. Invasive ventilation provides respiratory support through intratracheal tube. Noninvasive ventilation providing respiratory support via a ventilator and a nasal or facial mask may suffice to support ventilation until rapid improvement is observed with corticosteroids, and weaning becomes possible.
North America was observed as the leading regional eosinophilic pneumonia treatment market in the base year 2015. Rising prevalence of disease in soldiers is increasing the demand for treatment, and high awareness specific to diagnosis of respiratory disorders are expected to be the key market drivers during the forecast period throughout the forecast period 2016 – 2022. Asia Pacific was observed as the fastest growing market during the forecast period due to exponential growth in terms of healthcare infrastructure, disease awareness and treatment support from governmental and non-governmental bodies, and rising accessibility to enhanced diagnostic and treatment technologies.
The global eosinophilic pneumonia treatment market is segmented on the following bases:
1. Type of Disease
a. Acute Eosinophilic Pneumonia
b. Chronic Eosinophilic Pneumonia
2. Type of Drug class
a. Corticosteroids
b. Anti-inflammatory Drugs
c. Bronchodilators
d. Anti-IL-5
3. Geography
a. North America
i. US
ii. Canada
b. Europe
i. UK
ii. Germany
iii. Rest of Europe
c. Asia-Pacific
i. Japan
ii. China
iii. Rest of APAC
d. Latin America
e. Middle East and Africa
Key Players Identified for Eosinophilic Pneumonia Treatment Market Include but are Not Limited to:
Abbott Laboratories, Merck & Co., Sanofi S.A., Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers Squibb Company, Merck & Co., Johnson & Johnson and Pfizer Inc. and others.
This report offers:
- An overview of the global markets for eosinophilic pneumonia treatment
- Market trends assessment for the period 2014-2022, with historical information for 2014 & 2015, and projections through 2022, with respective CAGRS during 2016-2022
- Qualitative assessment tools such as market drivers, challenges and opportunities
- Market competition scrutiny tools such as market share analysis, fractal map assessment, Porter’s Five Forces model
- Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics.
- A general overview of the industry structure
- Company profiles highlighting key information about the major players operating in the eosinophilic pneumonia treatment market
